Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the amebiasis market?

In recent times, there has been a significant expansion in the size of the amebiasis market. It is expected to escalate from $0.82 billion in 2024 to $0.88 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. The growth in the previous period can be ascribed to the surge in amoebic infections in tropical zones, the prevalence of unsanitary conditions and poor hygiene habits in developing nations, an increase in international travel, notably to endemic regions, enhanced awareness surrounding the disease, and the absence of clean drinking water supplies in rural areas.

What will be the amebiasis market size in the future?

In the coming years, the market for amebiasis is projected to see robust growth, reaching $1.14 billion in 2029, with a compound annual growth rate of 6.6%. This growth during the forecast period can be attributed to factors such as the growing number of immune-compromised individuals, increased government efforts to better sanitation and healthcare facilities, significant investment in research for novel treatments, heightened focus on initiatives to fight against parasitic illnesses, and the growing demand for effective oral drugs. Key trends in the forecast period involve the increasing use of combined therapies, vaccine development, progress in drug delivery systems, advances in pharmaceutical research, and the creation of new antiprotozoal medications.

Get your amebiasis market report here!

https://www.thebusinessresearchcompany.com/report/amebiasis-global-market-report

What main drivers are fueling expansion in the amebiasis market?

Rising incidents of parasitic infection are projected to drive expansion in the amebiasis market. Diseases yielded by parasites such as protozoa, helminths or ectoparasites—which inhabit a host and feed off its resources—are named as parasitic infections. The upsurge in these infections can be ascribed to factors including enhanced travel, climatic alterations, sanitation inadequacies and increased drug-resistance; these conditions altogether facilitate the spread and sustenance of the infections. The parasitic infections include amebiasis, instigated by the parasite entamoeba histolytica. Amebiasis can invade the intestines and cause diarrhea, abdominal pain, potential tissue damage and liver abscesses. Citing January 2024 statistics from the UK’s Animal and Plant Health Agency, in 2022, there were 1,071 diagnoses of Parasitic Gastroenteritis (PGE), comprising 190 cases of haemonchosis and 95 instances of nematodirosis. The incidence of haemonchosis in 2022 was notably higher than the year before. Hence, the surge in parasitic infections is fostering growth in the amebiasis market. Impacts of Insufficient Sanitation on Market Expansion

What key areas define the segmentation of the global amebiasis market?

The amebiasis market covered in this report is segmented –

1) By Type: Metronidazole, Paromomycin, Tinidazole

2) By Route Of Administration: Oral, Intravenous

3) By Application: Hospital, Pharmacy

Subsegments:

1) By Metronidazole: Oral Metronidazole, Intravenous Metronidazole, Combination Therapy with Metronidazole

2) By Paromomycin: Oral Paromomycin, Paromomycin in Combination with Other Drugs

3) By Tinidazole: Oral Tinidazole, Tinidazole for Severe Infections

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21094&type=smp

Who are the dominant players expanding their reach in the amebiasis market?

Major companies operating in the amebiasis market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Cepheid Inc., Mission Pharmacal Company, Profounda Inc., Zydus Lifesciences Limited

How are evolving market trends shaping amebiasis Strategies?

The primary firms in the amebiasis market are concentrating their efforts on the creation of progressive solutions, such as metronidazole in a ready-to-use oral liquid form, with the aim of enhancing patient compliance and the effectiveness of treatment. This ready-to-use oral liquid metronidazole, a pre-prepared liquid rendering of the antibiotic used for treating diseases such as amebiasis, simplifies medication for those patients who find it difficult to swallow pills. In November 2023, Kesin Pharma Corporation, a pharmaceutical company located in the USA, was granted approval by the U.S. Food and Drug Administration for Likmez (metronidazole) oral suspension, 500mg/5mL; this is the premier ready-to-use oral liquid variant of metronidazole. This oral suspension version is a more amenable option for children, facilitating easy consumption, precise dosage, and improved adherence to treatment directives. The liquid version also provides the advantage of dosage flexibility, enabling healthcare professionals to alter treatment to suit the specific requirements of each patient, especially in cases of variable infection intensity.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21094

Which regions are emerging as leaders in the amebiasis market?

North America was the largest region in the amebiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amebiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Hepatitis B Virus (HBV) Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Viral Hepatitis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Global Cough And Cold Preparations Global Market Report 2025

https://thebusinessresearchcompany.com/report/cough-and-cold-preparations-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: